TY - JOUR
T1 - Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals
T2 - Results from an inter-cohort analysis
AU - Puoti, Massimo
AU - Cozzi-Lepri, Alessandro
AU - Arici, Claudio
AU - Moller, Nina Friis
AU - Lundgren, Jens D.
AU - Ledergerber, Bruno
AU - Rickenbach, Martin
AU - Suarez-Lozano, Ignacio
AU - Garrido, Myriam
AU - Dabis, Francois
AU - Winnock, Maria
AU - Milazzo, Laura
AU - Gervais, Anne
AU - Raffi, Francois
AU - Gill, John
AU - Rockstroh, Juergen
AU - Qurishi, Nazifa
AU - Mussini, Cristina
AU - Castagna, Antonella
AU - De Luca, Andrea
AU - Monforte, Antonella D Arminio
PY - 2006
Y1 - 2006
N2 - Background: The impact of lamivudine (3TC) as part of combination antiretroviral therapy (cART) on the risk of liver-related death (LRD) in HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively studied. Methods: We performed an analysis involving HIV/HBV-coinfected patients in 13 cohorts who initiated cART. The end-point was LRD - that is, death with concomitant decompensated liver disease (DLD) or hepatocellular carcinoma - as the main cause. Incidence rates of LRD after initiation of cART were expressed as number of events per 100 person-years of follow-up (PYFU). A Poisson regression model adjusted for cohort, gender, mode of HIV transmission, CD4 + T-cell count at cART initiation, liver disease pre-cART, duration of 3TC before cART, and hepatitis C virus was used to assess the association between use of 3TC and risk of LRD. Results: We analysed 2,041 patients. Follow-up after starting cART was 7.648 PYFU (5,569 spent on 3TC-containing regimens) with a median per person of 48 months (range: 2-91). Of the total, 217 subjects died; 57 deaths were liver-related resulting in a rate of 7.5 per 1,000 PYFU [95% confidence intervals (CI): 5.6-9.7]. The relative risk of LRD per extra year of 3TC use was 0.73 (95% CI: 0.59-0.90, P=0.004). Conclusion: The use of 3TC was associated with a reduced risk of LRD over 4 years of follow-up. This study supports the current view that the use of 3TC as part of cART should be considered in patients who are tested positive for HBsAg.
AB - Background: The impact of lamivudine (3TC) as part of combination antiretroviral therapy (cART) on the risk of liver-related death (LRD) in HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively studied. Methods: We performed an analysis involving HIV/HBV-coinfected patients in 13 cohorts who initiated cART. The end-point was LRD - that is, death with concomitant decompensated liver disease (DLD) or hepatocellular carcinoma - as the main cause. Incidence rates of LRD after initiation of cART were expressed as number of events per 100 person-years of follow-up (PYFU). A Poisson regression model adjusted for cohort, gender, mode of HIV transmission, CD4 + T-cell count at cART initiation, liver disease pre-cART, duration of 3TC before cART, and hepatitis C virus was used to assess the association between use of 3TC and risk of LRD. Results: We analysed 2,041 patients. Follow-up after starting cART was 7.648 PYFU (5,569 spent on 3TC-containing regimens) with a median per person of 48 months (range: 2-91). Of the total, 217 subjects died; 57 deaths were liver-related resulting in a rate of 7.5 per 1,000 PYFU [95% confidence intervals (CI): 5.6-9.7]. The relative risk of LRD per extra year of 3TC use was 0.73 (95% CI: 0.59-0.90, P=0.004). Conclusion: The use of 3TC was associated with a reduced risk of LRD over 4 years of follow-up. This study supports the current view that the use of 3TC as part of cART should be considered in patients who are tested positive for HBsAg.
UR - http://www.scopus.com/inward/record.url?scp=33747808649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747808649&partnerID=8YFLogxK
M3 - Article
C2 - 16964824
AN - SCOPUS:33747808649
VL - 11
SP - 567
EP - 574
JO - Antiviral Therapy
JF - Antiviral Therapy
SN - 1359-6535
IS - 5
ER -